摘要
目的探讨利妥昔单抗在B细胞非霍奇金淋巴瘤治疗中的临床应用价值。方法 B细胞非霍奇金淋巴瘤患者64例随机分成观察组和对照组各32例。对照组采用CHOP方案治疗;观察组采用利妥昔单抗+CHOP方案治疗。观察和比较2组患者临床疗效、免疫功能变化、主要不良反应的发生率。结果观察组临床总有效率为87.50%,高于对照组的50.00%(P<0.05);2组治疗后CD_4^+、CD_8^+、CD_4^+/CD_8^+B淋巴细胞及NK细胞均较治疗前显著改善,且观察组治疗后的B淋巴细胞指标值明显低于对照组(P<0.05)。观察组白细胞下降、血小板减少、恶心呕吐、重度贫血、肝功能损害、脱发等不良反应的发生率均略小于对照组(P>0.05)。结论采用利妥昔单抗+CHOP方案治疗B细胞非霍奇金淋巴瘤的临床效果显著。
Objective To investigate the therapeutic effect of rituximab on B cell non-Hodgkin lymphoma.Methods The 64 cases of elderly type 2 diabetic nephropathy patients admitted to hospital from January 2010 to December 2011 were randomly divided into two groups,control group（n =32） and treatment group（n =32）.The control group was treated with CHOP regimen,and the treatment group was treated with rituximab and CHOP regimen.The clinical effects,the incidence of adverse reactions and the changes of immune function in 2 groups were observed and compared.Results The total effective rate was 87.50%in the treatment group,and 50.00%in the control group,therefore the clinical effects in the treatment group was significantly better than the control group（P 0.05）.Conclusion There is a significant clinical effect of rituximab combined with CHOP for the treat- ment of B cell non-Hodgkin lymphoma.
出处
《疑难病杂志》
CAS
2012年第9期674-675,共2页
Chinese Journal of Difficult and Complicated Cases
